Human Caucasian B-prolymphocytic leukaemia, EBV-transformed
Cell Line Description
JVM-2 has been derived from EBV and TPA treated mononuclear cells from a 63 year old female patient with B-prolymphocytic leukaemia. Thirty-three percent of cells were shown to be positive for surface lambda light chain, 37% for IgA, 29% for IgG and 3% for IgM and IgD. In addition, 50% were found to express cytoplasmic IgM and lambda light chain. Expression of the following leukocyte differentiation antigens was found: CD9, CD19, CD20, CD23, CD24, MA6, CD37, CD38, FMC1, FMC7, MHC Class I, FMC16, MHC Class II DR/DP/DQ. The immunoglobulin heavy-and light-chain genes showed the same pattern of rearrangement as in the original prolymphocytes. The cells are lymphoblastoid with large floating aggregates present. The cell line has been eradicated from mycoplasma at ECACC.
Maintain cultures between 3-9 x 100,000/ml; 5% CO2; 37°C.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.